Cancer researcher presents technology developed to help personalize chemotherapy
He says more evaluation of the technology is needed, but a clinical trial on a small number of patients found ChemoID 100 percent accurate in predicting which drug is more effective in treating patients affected by brain cancer if the cancer stem-like cells are evaluated.
The upshot for a cancer patient, he says, is that ChemoID may make possible personalized treatment by predicting the most effective drug combination to successfully target that specific patient’s cancer—increasing the chance the drugs will work and perhaps reducing side effects by helping the patient avoid unnecessary drugs.
Claudio acknowledged the contributions of Dr. Anthony Alberico, chairman of the Department of Neuroscience at the Joan C. Edwards School of Medicine, for providing the clinical samples, as well as his co-investigators at the school of medicine, McKown Translational Genomics Research Institute and Edwards Comprehensive Cancer Center.
Marshall University 1 John Marshall Drive Huntington,